Delivery Order SPE2DB22D6029-SPE2DB25FLUSS

Award Date 4/1/25
Potential Completion Date 4/2/25
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of OTEZLA 30 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $18,819.70. It is a firm fixed-price, delivery order contract with a period of performance through February 11, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OTEZLA 30 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $27,839.98. The contract is a firm fixed-price delivery order, with a period of performance through February 12, 2025. The contract does not have a set-aside designation, indicating open competition....
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $10,471.44 contract is for the delivery of OTEZLA 30 MG TABLET 60S, a prescription medication. The contract has a completion date of December 11, 2024 and is a Firm Fixed Price arrangement. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Otezla 30 mg tablets. The contract has a ceiling value of $96,872.70 and a period of performance through August 27, 2024. It is a firm fixed-price delivery order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OTEZLA 30 MG TABLET 60S, a specialty medication, with a ceiling value of $21,006.15 and a period of performance through December 2, 2024. The contract is a Firm Fixed Price type and was not set aside for any specific business categories. AmerisourceBergen holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of OTEZLA 30 mg tablets. The contract has a ceiling value of $40,332.44 and an ultimate completion date of September 30, 2024. This delivery order falls under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for the provision of a comprehensive range of...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OTEZLA 30 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $27,231.74 and a period of performance through November 24, 2023. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,132.83, is for the supply of Otezla 30 mg tablets. It is a firm fixed-price contract with a period of performance through March 24, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OTEZLA 30 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $78,876.22 and a period of performance through February 5, 2025. The contract is a Firm Fixed Price (FFP) type and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OTEZLA 30 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $3,072.64. The contract is a firm fixed-price Indefinite Delivery Contract (IDC) that runs through March 31, 2025. No set-aside designation was used for this award. AmerisourceBergen holds a larger...
  • SPE2DB22D6029
    Indefinite Delivery Contract
  • SPE2DB22D6029-SPE2DB25FLUSS
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OTEZLA 30 MG TABLET 60S. The contract has a firm fixed price, a ceiling value of $11,064.07, and a period of performance through April 2, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 7/1/25, 2:40 PM